NCT04485364View on ClinicalTrials.gov

Place of Circulating Biomarkers and Respiratory Eicosanoids in the Prognosis of Severe Forms of Covid-19 Pneumonia

CompletedOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

April 14, 2020

Primary Completion Date

May 31, 2022

Study Completion Date

June 6, 2022

Conditions

CoronavirusCovid19

Trial Locations (1)

75014

Groupe Hospitalier Paris Saint-Joseph, Paris

All Listed Sponsors

collaborator

Versailles Hospital

OTHER

collaborator

Centre Hospitalier Victor Dupouy

OTHER

lead

Fondation Hôpital Saint-Joseph

OTHER

NCT04485364 - Place of Circulating Biomarkers and Respiratory Eicosanoids in the Prognosis of Severe Forms of Covid-19 Pneumonia | Biotech Hunter | Biotech Hunter